Literature DB >> 2758384

Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program.

T Hatschek1, G Fagerberg, O Stål, S Sullivan, J Carstensen, O Gröntoft, B Nordenskjöld.   

Abstract

A randomized controlled trial evaluating mammographic screening was started in two Swedish counties in 1977. In one of these, Ostergötland county, the authors performed static cytofluorometry on 161 cancers detected at the second and third screening rounds, 50 interval cancers, and 219 cancers appearing in the nonscreened control group during the same time period. The median follow-up time was 42 months. No difference in mean S-phase was found between screening and control group cancers, but interval cancers, appearing between two screenings, had increased mean S-phase levels (P = 0.01) compared to both of the other groups. A high S-phase fraction was associated with distant recurrence in both node-negative and node-positive tumors. Aneuploid tumors were more often found in the control group (67%) and among interval cancers (72%) than among screening detected cancers (55%, P = 0.02). In Cox's multivariate analysis, including all patients, the lymph node status, tumor size, estrogen receptor content, and S-phase all contributed independent prognostic information about the clinical course. DNA ploidy predicted the outcome in simple but not in multivariate Cox's analysis. When analyzing screening-detected cancers separately, only the S-phase significantly predicted distant recurrence in multivariate analysis. In tumors with local recurrence, a high S-phase implicated an increased, although not statistically significant, risk for distant recurrence. Survival with metastatic disease was significantly influenced by the S-phase level (P = 0.002). The authors conclude that S-phase fraction provides valuable kinetic information related to the clinical outcome for all stages of the disease and serves as a prognostic factor in screened populations, which have tumors predominantly in early stages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758384     DOI: 10.1002/1097-0142(19890901)64:5<1074::aid-cncr2820640519>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence.

Authors:  T Hatschek; O Gröntoft; G Fagerberg; O Stål; S Sullivan; J Carstensen; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

2.  Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas.

Authors:  S B Ewers; R Attewell; B Baldetorp; A Borg; E Långström; D Killander
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

3.  Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial.

Authors:  T Hatschek; J Carstensen; G Fagerberg; O Stål; O Gröntoft; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

4.  Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer.

Authors:  D W Visscher; S Wykes; J Kubus; J D Crissman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 5.  Screening for breast cancer with mammography.

Authors:  Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

6.  Histological features, DNA content and prognosis of breast carcinoma found incidentally or in screening.

Authors:  H Joensuu; S Toikkanen; P J Klemi
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

7.  Comparative pathology of breast cancer in a randomised trial of screening.

Authors:  T J Anderson; J Lamb; P Donnan; F E Alexander; A Huggins; B B Muir; A E Kirkpatrick; U Chetty; W Hepburn; A Smith
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

8.  Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

Authors:  O Stål; J Carstensen; T Hatschek; B Nordenskjöld
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

9.  DNA aneuploidy in early breast cancer.

Authors:  G L Ottesen; I J Christensen; J K Larsen; G B Kerndrup; B Hansen; J A Andersen
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.